Know Cancer

or
forgot password

A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer


Phase 3
N/A
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer


The study will investigate the efficacy, pharmacokinetics and safety of two subcutaneous
injections of triptorelin embonate 22.5 mg 6-month formulation in patients with prostate
cancer. The total duration of the study per patient will be 12 months (48 weeks)


Inclusion Criteria:



- Histologically or cytologically proven prostate cancer.

- Prostate cancer stage T3-4NxMx, TxN1Mx or TxNxM1 according to the TNM classification
(see Appendix A: TNM Classification) or the patient should have rising PSA after
failed local therapy and be candidate for androgen deprivation therapy.

- Serum testosterone levels > 5 nmol/L.

- Karnofsky performance index > 40 (see Appendix B: Karnofsky Performance Scale).

- Expected survival > 18 months.

- Absence of another malignancy, other than local dermatological, for the previous 5
years.

- Signed informed consent before entry into the study.

Exclusion Criteria:

- Prior hormonal treatment for prostate cancer within 6 months prior to study start.

- Use of finasteride (ProscarĀ®) or dutasteride (AvodartĀ®/AvolveĀ®) within 2 months prior
to study start.

- Presence of another neoplastic lesion or brain metastases.

- Prior hypophysectomy or adrenalectomy.

- Known or suspicion of vertebral metastases with risk of spinal compression.

- Severe kidney or liver failure (creatinine > 2 x upper limit of normal (ULN),
aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) > 3 x ULN).

- Any concomitant disorder or resulting therapy that is likely to interfere with
patient compliance or with the study in the opinion of the Investigator.

- Participation in another study with an experimental drug within 3 months before study
start or within 5 drug half-lives of the investigational drug (whichever is the
longer).

- Known hypersensitivity to any of the test materials or related compounds.

- Known active use of recreational drug or alcohol dependence in the opinion of the
Investigator.

- Any current use or use within 6 months prior to treatment start of medications which
are known to affect the metabolism and/or secretion of androgenic hormones:
ketoconazole, aminoglutethimide, oestrogens, progesterone, and anti-androgens.

- Use of systemic or inhaled corticosteroids (topical application permitted).

- Inability to give informed consent or to comply fully with the protocol.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary Efficacy

Outcome Description:

Percentage of patients achieving castrate levels of serum testosterone (< 1.735 nmol/L) by Day 29. Percentage of patients maintaining castrate levels of serum testosterone (< 1.735 nmol/L) from Month 2 (Day 57) to end of Month 12 (Day 337).

Outcome Time Frame:

Month 1 (Day 29) and from Month 2 (Day 57) to end of Month 12 (Day 337)

Safety Issue:

No

Principal Investigator

Eija Lundstrom, MD

Investigator Role:

Study Director

Investigator Affiliation:

Debiopharm SA

Authority:

South Africa: Medicines Control Council

Study ID:

Debio 8206-SC-301

NCT ID:

NCT01656161

Start Date:

July 2012

Completion Date:

November 2013

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location